Fighting Omicron: This Covid Vaccine Candidate Is Going After The Dangerous Mutation

• CureVac N.V. (NASDAQ: CVAC) and GSK plc (NYSE: GSK) have started a Phase 1 trial of the modified COVID-19 mRNA vaccine candidate, administered as a booster dose to previous COVID-19 vaccination.

• The candidate, CV0501, is meant to be administered as a booster dose following the previous COVID-19 vaccination. GSK used CureVac's "second-generation mRNA backbone" to develop the vaccine.

• CureVac will test CV0501 in up to 180 healthy, COVID-19 vaccinated adults. The participants will receive a single booster dose in the dose range of 12µg to 50µg at first.

• Related: BioNTech, Pfizer File For Clearance Over COVID-19 Vaccine Patent Dispute With CureVac.

• Additional dose levels below 12µg and above 50µg may be evaluated if supported by safety and immunogenicity data at these dose levels.

• In March, the company also kicked off a phase 1 test for a "second-generation" COVID-19 shot called CV2CoV.

• The company said this double-pronged approach would help identify the best-performing candidate for later-stage clinical development.

• Data from the two studies will be reported together, although CureVac did not say when.

• Price Action: CVAC shares are down 0.08% at $13.17, and GSK stock is down 1.92% at $34.04 on the last check Thursday.

• Photo by Gerd Altmann from Pixabay

See more from Benzinga

• AstraZeneca Slaps Lawsuit Against Former Employee As He Moves To Close Rival: Report

• GSK's Rare Blood Cancer Candidate Goes Under FDA Review

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.